The NIH Office of Disease Prevention Pathway to Prevention (P2P) program approved a proposal for a workshop to provide an evidence-based assessment on ME/CFS. We first wrote about the P2P workshop program in April (http://solvecfs.org/pathways-to-prevention-for-mecfs/). Since then we have been working with the advocacy community to stay abreast of the P2P process and assess its impact on ME/CFS.
We applaud the fact that a P2P is focusing on ME/CFS but we have concerns about the evidenced-based literature review. We have reviewed the most recent protocol posted by AHRQ evidence-based assessment center on May 1, 2014 (read it HERE ) and have identified serious flaws with the sample search strategy described in the appendix.
This search and corresponding criteria will bias the evidence base to cognitive behavioral therapy (CBT) and graded exercise therapy (GET) trials – treatment approaches that are not specific to ME/CFS (as noted by AHRQ) – and will not assess any of the important biomarker research that has been conducted and funded (primarily) by NIH over the past 25 years. This is unacceptable. The search criteria must be broader and must include terms that reflect the important advances that have been made in biomarker research for ME/CFS. We believe it is not too late to correct this and that many stakeholders would be willing to participate to help make the P2P as effective as possible.
We have written a letter to Paris A. Watson, Senior Advisor, NIH Office of Disease Prevention, Susan E. Maier, Ph.D., Deputy Director, NIH Office of Research on Women’s Health, David M Murray, Ph.D., Associate Director for Prevention, Director of the Office of Disease Prevention, and Francis S. Collins, M.D., Ph.D., NIH Director to address these concerns. You can read our letter to the NIH concerning the P2P HERE.
It is imperative that this P2P workshop address gaps in research because it is plausible that the NIH will use the P2P evidence-based report to inform a new ME/CFS funding opportunity – the current program announcement expires October 25, 2014 (http://grants.nih.gov/grants/guide/pa-files/PAR-12-032.html).
We have requested that the NIH tell the ME/CFS community whether the P2P will inform a new NIH funding opportunity. If so, it is critically important that the P2P go forward with an evidence-based review that will result in a compelling funding opportunity that attracts investigators to ME/CFS research.
Dr Suzanne Vernon, the Solve ME/CFS Initiative’s Scientific Director continues to serve on the working group, (made up of content experts in ME/CFS – clinicians, researchers, patients, patient advocates, caregivers and Federal partners). Though the work done they have done to date is limited, she will remain engaged in order to help make this ME/CFS P2P workshop the best it can be. She is working to bring attention to the flaws in this evidence-based process in the hopes that the P2P will fix it and get it right. We are happy that Dr Vernon is serving in this capacity and able to lend her expertise to the proceedings.
Our understanding is that there will be opportunity to comment and offer feedback on this report; that at the two-day workshop, the P2P panel will hear from the expert speakers and be able to ask clarifying questions in a town-hall-like Q&A that will take place after each session during the meeting. We will bring you information on how and when to participate as soon as it is available so that together we can do all we can to ensure the resultant recommendations are aimed at improving the robust nature of the research into ME/CFS.
Read our earlier blog post that explained the P2P process HERE
Read more about the Pathway to Prevention workshop program HERE
Read more about the systematic evidence review being performed by AHRQ HERE
Tags: CFS research, Developing Drug Products for ME/CFS, federal, ME/CFS, ME/CFS News, ME/CFS Research, ME/CFS Update, NIH, P2P, Pathway to Prevention June 12, 2014